Publicacions en col·laboració amb investigadors/es de University Hospital of Geneva (21)

2017

  1. CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: A multinational, multicohort European study

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 10, pp. 2869-2878

2016

  1. Infection-related and -unrelated malignancies, HIV and the aging population

    HIV Medicine, Vol. 17, Núm. 8, pp. 590-600

  2. The global spread of HIV-1 subtype B epidemic

    Infection, Genetics and Evolution, Vol. 46, pp. 169-179

2015

  1. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study

    HIV Medicine, Vol. 16, Núm. 9, pp. 533-543

  2. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

2014

  1. A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

    Infection, Vol. 42, Núm. 4, pp. 757-762

  2. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: The D:A:D study

    BMC Nephrology, Vol. 15, Núm. 1

2013

  1. Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients

    PLoS ONE, Vol. 8, Núm. 5

2012

  1. Hepatitis c virus viremia increases the Incidence of chronic kidney disease in HIV-infected Patients

    AIDS, Vol. 26, Núm. 15, pp. 1917-1926

  2. Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: The EuroSIDA study

    PLoS ONE, Vol. 7, Núm. 7

2011

  1. A376s in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy

    Journal of Infectious Diseases, Vol. 204, Núm. 5, pp. 741-752

  2. European recommendations for the clinical use of HIV drug resistance testing: 2011 update

    AIDS Reviews, Vol. 13, Núm. 2, pp. 77-108

  3. Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naïve HIV-2-infected patients: The ACHIEV2E collaboration study group

    Clinical Infectious Diseases, Vol. 52, Núm. 10, pp. 1257-1266

2010

  1. Dialysis and renal transplantation in HIV-infected patients: A European survey

    Journal of Acquired Immune Deficiency Syndromes, Vol. 55, Núm. 5, pp. 582-589

2009

  1. Tracing the HIV-1 subtype B mobility in Europe: A phylogeographic approach

    Retrovirology, Vol. 6

  2. Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS-Defining Conditions Are Created Equal

    Clinical Infectious Diseases, Vol. 48, Núm. 8, pp. 1138-1151

2008

  1. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA

    AIDS, Vol. 22, Núm. 3, pp. 367-376

2006

  1. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes

    Journal of Acquired Immune Deficiency Syndromes, Vol. 41, Núm. 3, pp. 352-360

2005

  1. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management

    Journal of Infectious Diseases, Vol. 192, Núm. 6, pp. 958-966

2004

  1. Updated European recommendations for the clinical use of HIV drug resistance testing

    Antiviral Therapy, Vol. 9, Núm. 6, pp. 829-848